Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120107390 | FELINE INFECTIOUS PERITONITIS VACCINE FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer prevent... | 05/03/2012 |
| 20120082643 | Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response The present invention provides compositions and methods for the treatment and prevention of immune disorders.... | 04/05/2012 |
| 20120082693 | USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S... | 04/05/2012 |
| 20120070454 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of ... | 03/22/2012 |
| 20120070456 | POLYPEPTIDE CARRIER PROTEIN The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vacci... | 03/22/2012 |
| 20120070455 | INFLUENZA VACCINE The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antib... | 03/22/2012 |
| 20120052082 | CROSS-PROTECTIVE INFLUENZA VACCINE A cross-protective influenza virus vaccine has been designed based on the incorporation of the genetically engineered, highly conserved M2 influenza viral protein optionally in combination with an adjuvant such as a bacterial flagellin protein incorporated into the memb... | 03/01/2012 |
| 20120045469 | VACCINE The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an oil-in-water emulsion.... | 02/23/2012 |
| 20120045413 | Human papilloma virus peptide-specific T-cell response for treatment of warts The inventors have treated human patients for warts by intralesional injection of Candida antigen to induce a delayed-type hypersensitivity response in the patients. This creates an immune response that recognizes the antigens of the human papilloma virus (HPV) f... | 02/23/2012 |
| 20120045467 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV prote... | 02/23/2012 |
| 20120045468 | Immunogenic Compositions and Uses Thereof Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.... | 02/23/2012 |
| 20120039921 | POULTRY VIRAL MATERIALS AND METHODS RELATED THERETO The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis diseas... | 02/16/2012 |
| 20120039922 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an infl... | 02/16/2012 |
| 20120034253 | Influenza Vaccines, Antigens, Compositions, and Methods The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, ... | 02/09/2012 |
| 20120027789 | ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demons... | 02/02/2012 |
| 20120027771 | AFFINITY PURIFIED HUMAN POLYCLONAL ANTIBODIES AGAINST VIRAL, BACTERIAL AND/OR FUNGAL INFECTIONS AND METHODS OF MAKING AND USING THE SAME The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified f... | 02/02/2012 |
| 20120027788 | SIMIAN ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleoti... | 02/02/2012 |
| 20120027792 | EXPRESSION VECTORS ABLE TO ELICIT IMPROVED IMMUNE RESPONSE AND METHODS OF USING SAME The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is incr... | 02/02/2012 |
| 20120027790 | IMMUNOLOGICAL HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR USE THEREOF The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells hav... | 02/02/2012 |
| 20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of th... | 01/19/2012 |
| 20120009254 | Respiratory Syncytial Virus Antigenic Compositions and Methods Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes... | 01/12/2012 |
| 20120003255 | FLAVIVIRUS HOST-RANGE MUTATIONS AND USES THEREOF Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalia... | 01/05/2012 |
| 20110318355 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, su... | 12/29/2011 |
| 20110318376 | RECOMBINANT EXPRESSION OF SELF-FOLDING NEUTRALIZING EPITOPE-BEARING SUBDOMAINS OF THE RESPIRATORY SYNCYTIAL VIRUS ATTACHMENT AND FUSION PROTEINS The present invention is directed to self-folding, soluble, stable RSV G and F polypeptides that contain a neutralizing epitope. Fusion proteins and immunogenic conjugates containing the RSV G and F polypeptides, along with recombinant transgenes and vectors, and host c... | 12/29/2011 |
| 20110311614 | SPLITTING GP41 The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proxima... | 12/22/2011 |
| 20110311541 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, su... | 12/22/2011 |
| 20110311568 | Vaccine The present invention provides a foot and mouth disease (FMD) vaccine comprising or capable of expressing afoot and mouth disease virus (FMDV) VP1 polypeptide having a deletion of at least seven amino acids in the G-H loop such that the VP1 polypeptide lacks an RGD moti... | 12/22/2011 |
| 20110300168 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST INFLUENZA ANTIGENS This disclosure provides compositions and methods for inducing an immune response against influenza antigens, for example in elderly populations, as well as a sensitive artificial antigen presenting cell (aAPC) stimulation assay that can be used for expansion and analys... | 12/08/2011 |
| 20110300149 | LJUNGAN VIRUS The present invention relates to a new group of Ljungan viruses, proteins expressed by the viruses, antibodies to the viruses and proteins, vaccines against the viruses, diagnostic kits for detecting the viruses, uses of the viruses, proteins, antibodies and vaccines in... | 12/08/2011 |
| 20110293649 | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after va... | 12/01/2011 |
| 20110293651 | HPV E6 protein T cell epitopes and uses thereof The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes ... | 12/01/2011 |
| 20110293650 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention i... | 12/01/2011 |
| 20110293621 | IMMUNOGENIC POLYPEPTIDES COMPRISING A SCAFFOLD POLYPEPTIDE AND A L2 POLYPEPTIDE OR A FRAGMENT THEREOF The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2... | 12/01/2011 |
| 20110287044 | RECOMBINANT CLASSICAL SWINE FEVER VIRUS (CSFV) COMPRISING A MODIFIED E2 PROTEIN AND METHODS FOR GENERATING SAID RECOMBINANT CSFV The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant C... | 11/24/2011 |
| 20110280899 | Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects ag... | 11/17/2011 |
| 20110274702 | NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also rel... | 11/10/2011 |
| 20110274705 | METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS The present invention is directed to novel compositions that cause effective redirection of class I-immunity to Tc1 effectors, that take advantage of the unexpected loading of MHC I by peptide within IgG backbone combined with appropriate instruction of antigen presenti... | 11/10/2011 |
| 20110274710 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in... | 11/10/2011 |
| 20110262529 | CYTOTOXIC T CELL EPITOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24.... | 10/27/2011 |
| 20110262472 | VACCINE COMPOSITIONS FOR THE TREATMENT OF DENGUE FEVER AND USES THEREOF The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like par... | 10/27/2011 |
